Academic Journal
Προβολή σε EDS

Comparative effectiveness and safety of proton pump inhibitors after myocardial infarction on dual antiplatelet therapy: Insights from a target trial emulation.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Comparative effectiveness and safety of proton pump inhibitors after myocardial infarction on dual antiplatelet therapy: Insights from a target trial emulation.
Συγγραφείς: Zhao L; Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China., Li L; Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China., Wu C; Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China., Liu H; Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China., Aa G; Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China., Chen X; Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China., Zhang Z; Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China., Chew NWS; Yong Loo-Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Cardiology, National University Heart Centre, Singapore, Singapore., Chan MYY; Yong Loo-Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Cardiology, National University Heart Centre, Singapore, Singapore.; Cardiovascular Research Institute, National University Health System, Singapore, Singapore., Sia CH; Yong Loo-Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Cardiology, National University Heart Centre, Singapore, Singapore., Tan DS; Department of Pharmacy and Pharmaceutical Sciences, National University Singapore Faculty of Science, Singapore, Singapore., Sun P; Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China., Zhou X; Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China., Yang Q; Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.
Πηγή: British journal of clinical pharmacology [Br J Clin Pharmacol] 2026 Oct; Vol. 92 (10), pp. 3466-3476. Date of Electronic Publication: 2026 Jun 17.
Τύπος έκδοσης: Journal Article; Comparative Study
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE
Imprint Name(s): Publication: Oxford : Wiley-Blackwell
Original Publication: London, Macmillan Journals Ltd.
Ιατρικοί όροι (MeSH): Proton Pump Inhibitors*/adverse effects , Proton Pump Inhibitors*/administration & dosage , Proton Pump Inhibitors*/therapeutic use , Myocardial Infarction*/drug therapy , Gastrointestinal Hemorrhage*/chemically induced , Gastrointestinal Hemorrhage*/prevention & control , Gastrointestinal Hemorrhage*/epidemiology , Platelet Aggregation Inhibitors*/adverse effects , Platelet Aggregation Inhibitors*/administration & dosage , Dual Anti-Platelet Therapy*/adverse effects , Dual Anti-Platelet Therapy*/methods, Pantoprazole/adverse effects ; Pantoprazole/administration & dosage ; Rabeprazole/adverse effects ; Rabeprazole/administration & dosage ; Lansoprazole/adverse effects ; Lansoprazole/administration & dosage ; Humans ; Female ; Male ; Aged ; Middle Aged ; Treatment Outcome ; Drug Therapy, Combination ; Proportional Hazards Models
Περίληψη: Background: Current guidelines recommend co-prescribing proton pump inhibitors (PPIs) with dual antiplatelet therapy (DAPT) after acute myocardial infarction (MI) to prevent gastrointestinal bleeding. Emerging evidence indicates that PPIs have distinct pharmacokinetic profiles, and their cardiovascular and bleeding effects may not represent a class effect.
Methods: We used electronic health record data from the Tianjin Health and Medical Data Platform to emulate target trials comparing effectiveness and safety of three commonly used PPIs in clinical practice. The effectiveness outcome was gastrointestinal bleeding, and the safety outcome was composite cardiovascular events. Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) between individual PPIs. We further applied XGBoost-based prognostic models to assess treatment effect heterogeneity across strata of predicted baseline risk.
Results: Of 51 072 MI patients on DAPT, 22 671 were prescribed rabeprazole, 18 081 pantoprazole and 10 320 lansoprazole. During 1 year of follow-up, both pantoprazole (HR, 1.05 [95% CI, 0.97-1.13]) and lansoprazole (HR, 0.99 [0.91-1.09]) showed comparable cardiovascular risk to rabeprazole, but pantoprazole was associated with an increased risk of recurrent MI (HR, 1.20 [1.07-1.35]). For gastrointestinal bleeding risk, lansoprazole showed lower risk (HR, 0.81 [0.70-0.93]) compared with rabeprazole. Results were robust in multiple sensitivity analyses, and treatment effect heterogeneity showed gastrointestinal benefits of lansoprazole increase with the rising baseline bleeding risk.
Conclusions: In patients with acute MI receiving DAPT, the three PPIs showed similar cardiovascular safety, while lansoprazole was associated with a lower risk of gastrointestinal bleeding. External validation is warranted to examine these findings.
(© 2026 British Pharmacological Society.)
References: Li L, Geraghty OC, Mehta Z, Rothwell PM, Oxford Vascular Study. Age‐specific risks, severity, time course, and outcome of bleeding on long‐term antiplatelet treatment after vascular events: a population‐based cohort study. Lancet. 2017;390(10093):490‐499. doi:10.1016/S0140‐6736(17)30770‐5.
Sehested TSG, Carlson N, Hansen PW, et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur Heart J. 2019;40(24):1963‐1970. doi:10.1093/eurheartj/ehz104.
Ogawa R, Echizen H. Drug‐drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49(8):509‐533. doi:10.2165/11531320‐000000000‐00000.
Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel‐proton pump inhibitor drug‐drug interaction and risk of adverse clinical outcomes among PCI‐treated ACS patients: a meta‐analysis. J Manag Care Spec Pharm. 2016;22(8):939‐947. doi:10.18553/jmcp.2016.22.8.939.
Lin MH, Wu WT, Chen YC, et al. Association between clinical use of lansoprazole and the risk of coronary heart disease: a nationwide pharmacoepidemiological cohort study. Cardiovasc Drugs Ther. 2025;39(6):1321‐1329. doi:10.1007/s10557‐024‐07643‐4.
Bueno, H., Byrne, R.A., Collet, J.P. et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. 2017.
Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2025;151(13):e771‐e862. doi:10.1161/CIR.0000000000001309.
Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five‐way crossover study. Am J Gastroenterol. 2003;98(12):2616‐2620. doi:10.1111/j.1572‐0241.2003.08783.x.
Department of Gastroenterology, Kocaeli University School of Medicine, Kocaeli, TurkeyCelebi A, Aydin D, et al. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turk J Gastroenterol. 2020;27(5):408‐414. doi:10.5152/tjg.2016.15514.
Xia B, He Q, Smith FG, et al. Individualized prevention of proton pump inhibitor related adverse events by risk stratification. Nat Commun. 2024;15(1):3591. doi:10.1038/s41467‐024‐48007‐8.
Kent DM, Paulus JK, Van Klaveren D, et al. The predictive approaches to treatment effect heterogeneity (PATH) statement. Ann Intern Med. 2020;172(1):35‐45. doi:10.7326/M18‐3667.
Sun P, Liu WN, Qian X, et al. Age‐specific prognosis of acute and steady minor elevations in cardiac troponin among non‐acute myocardial infarction inpatients: a large real‐world cohort study. Heart. 2025;111(11):513‐521. doi:10.1136/heartjnl‐2024‐325079.
Chen X, Liu H, Li L, et al. Atorvastatin versus rosuvastatin in acute myocardial infarction with elevated liver enzymes: a target trial emulation study. Clin Res Cardiol. 2025;114(6):796‐808. doi:10.1007/s00392‐025‐02645‐0.
Li L, A G, Guo Y, et al. Early β‐blocker use and clinical outcomes in acute myocardial injury: a retrospective cohort study. Am J Med. 2025;138(7):1090‐1098.e6. doi:10.1016/j.amjmed.2025.02.029.
Liu Y, Li L, Li J, et al. Development and validation of a predictive model for intracranial haemorrhage in patients on direct oral anticoagulants. Clin Appl Thromb/Hemost. 2024;30:10760296241271338. doi:10.1177/10760296241271338.
Shin H, Paik JM, Everett BM, et al. Comparative effectiveness of individual sodium‐glucose cotransporter 2 inhibitors. JAMA Intern Med. 2025;185(3):302‐313. doi:10.1001/jamainternmed.2024.7357.
Linden A, Mathur MB, VanderWeele TJ. Conducting sensitivity analysis for unmeasured confounding in observational studies using E‐values: the evalue package. Stata J. 2020;20(1):162‐175. doi:10.1177/1536867X20909696.
Alexander SPH, Kelly E, Mathie AA, et al. The concise guide to pharmacology 2023/24: introduction and other protein targets. Br J Pharmacol. 2023;180(S2):1‐22. doi:10.1111/bph.16176.
Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de‐prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022;162(4):1334‐1342. doi:10.1053/j.gastro.2021.12.247.
Carollo M, Crisafulli S, Selleri M, Piccoli L, L'Abbate L, Trifirò G. Agreement of different drug‐drug interaction checkers for proton pump inhibitors. JAMA Netw Open. 2024;7(7):e2419851. doi:10.1001/jamanetworkopen.2024.19851.
Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845‐853. doi:10.1161/CIRCULATIONAHA.113.003602.
Gulizia MM, Colivicchi F, Abrignani MG, et al. Consensus document ANMCO/ANCE/ARCA/GICR‐IACPR/GISE/SICOA: long‐term antiplatelet therapy in patients with coronary artery disease. Eur Heart J Suppl. 2018;20(suppl_F):F1‐F74. doi:10.1093/eurheartj/suy019.
Mosholder AD, Hada M, Leishear K. Proton‐pump inhibitors and cardiovascular adverse events: a meta‐analysis of randomized controlled trials. Am J Gastroenterol. 2025;120(2):362‐369. doi:10.14309/ajg.0000000000003058.
O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton‐pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989‐997. doi:10.1016/S0140‐6736(09)61525‐7.
Douglas IJ, Evans SJW, Hingorani AD, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ. 2012;345:e4388. doi:10.1136/bmj.e4388.
Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125(8):978‐986. doi:10.1161/CIRCULATIONAHA.111.032912.
Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909‐1917. doi:10.1056/NEJMoa1007964.
Kang D, Choi KH, Park H, et al. Effects of proton pump inhibitors on gastrointestinal bleeding and cardiovascular outcomes in myocardial infarction patients treated with DAPT. EuroIntervention. 2025;21(4):e229‐e239. doi:10.4244/EIJ‐D‐24‐00673.
Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French registry of acute ST‐elevation and non–ST‐elevation myocardial infarction (FAST‐MI) registry. Circulation. 2011;123(5):474‐482. doi:10.1161/CIRCULATIONAHA.110.965640.
Burkard T, Kaiser CA, Brunner‐La Rocca H, et al. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. J Intern Med. 2012;271(3):257‐263. doi:10.1111/j.1365‐2796.2011.02423.x.
Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690. doi:10.1136/bmj.d2690.
Maret‐Ouda J, Santoni G, Xie S, Rosengren A, Lagergren J. Proton pump inhibitor and clopidogrel use after percutaneous coronary intervention and risk of major cardiovascular events. Cardiovasc Drugs Ther. 2022;36(6):1121‐1128. doi:10.1007/s10557‐021‐07219‐6.
Tan CM, Juurlink DN. Navigating drug interactions with proton pump inhibitors. JAMA Netw Open. 2024;7(7):e2419818. doi:10.1001/jamanetworkopen.2024.19818.
Priyadharshini A, Vijayakumar TM, Damodharan N, Vasanth KM, Elaiyaraja A. Comparative in vitro assessment of CYP2C19 inhibition by ilaprazole and conventional proton pump inhibitors using a high throughput fluorometric assay. Sci Rep. 2025;15(1):18158. doi:10.1038/s41598‐025‐02872‐5.
Norgard NB, Mathews KD, Wall GC. Drug–drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009;43(7–8):1266‐1274. doi:10.1345/aph.1M051.
Shah NH, LePendu P, Bauer‐Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS ONE. 2015;10(6):e0124653. doi:10.1371/journal.pone.0124653.
Wang YF, Chen YT, Luo JC, Chen TJ, Wu JC, Wang SJ. Proton‐pump inhibitor use and the risk of first‐time ischemic stroke in the general population: a nationwide population‐based study. Am J Gastroenterol. 2017;112(7):1084‐1093. doi:10.1038/ajg.2017.101.
Mayor S. People taking proton pump inhibitors may have increased risk of myocardial infarction, study shows. BMJ. 2015;350:h3220. doi:10.1136/bmj.h3220.
Yepuri G, Sukhovershin R, Nazari‐Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton pump inhibitors accelerate endothelial senescence. Circ Res. 2016;118(12):e36‐e42. doi:10.1161/CIRCRESAHA.116.308807.
Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101(10):1206‐1218. doi:10.1161/01.cir.101.10.1206.
Luo JC, Peng YL, Chen TS, et al. Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2. J Formos Med Assoc. 2016;115(9):764‐772. doi:10.1016/j.jfma.2015.07.022.
Horn J. The proton‐pump inhibitors: similarities and differences. Clin Ther. 2000;22(3):266‐280. doi:10.1016/S0149‐2918(00)80032‐6.
McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012;8(3):371‐382. doi:10.1517/17425255.2012.657626.
Grant Information: 2022YFF0706000 National Key Research and Development Program of China; 72274133 National Natural Science Foundation of China; 72304205 National Natural Science Foundation of China; 82270349 National Natural Science Foundation of China; 82320108001 National Natural Science Foundation of China; 82321001 National Natural Science Foundation of China; TJYXZDXK-069C Tianjin Key Medical Discipline (Specialty) Construction Project
Contributed Indexing: Keywords: bleeding prevention; cardiovascular outcome; myocardial infarction; proton pump inhibitors
Substance Nomenclature: 0 (Proton Pump Inhibitors)
0 (Platelet Aggregation Inhibitors)
D8TST4O562 (Pantoprazole)
32828355LL (Rabeprazole)
0K5C5T2QPG (Lansoprazole)
Entry Date(s): Date Created: 20260617 Date Completed: 20260928 Latest Revision: 20260928
Update Code: 20260929
DOI: 10.1002/bcp.70650
PMID: 42309503
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1365-2125
DOI:10.1002/bcp.70650